Drug Trial Radar · NCT07951138
A Phase 1, Randomized, Open-Label, Single-Center, Single-Dose, Three-Period, Six-Sequence Crossover Study in Healthy Volunteers to Compare the Relative Bioavailability of Itraconazole Tablet (T26) and Itraconazole Capsule (Sporanox®) Under Fed Conditions and to Assess the Food Effect on T26
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Nov 16, 2026
Primary completion
Dec 19, 2026
Study completion Feb 2027
Sponsor
- Lead sponsor
- Triastek, lnc.Industry
- Sponsor type
- Industry
- First posted
- Nov 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase 1, randomized, open-label, single-center, single-dose, three-period, six-sequence crossover study in healthy adult volunteers. The study is designed to compare the relative bioavailability of itraconazole tablet (T26, Test) with itraconazole capsule (Sporanox®, Reference) under fed conditions; and to assess the food effect from a high-fat meal on T26. Three treatments, as described below, are planned: Test Product (Tfed): T26, 130 mg (two 65 mg tablets), administered under fed conditions Reference Product (R): Sporanox®, 200 mg (two 100 mg capsules), administered under fed conditions Test Product (Tfasted): T26, 130 mg (two 65 mg tablets), administered under fasted conditions A total of 18 participants will be randomized 1:1:1:1:1:1 into six different treatment sequences (TfastTfedR, TfastRTfed, TfedTfastR, TfedRTfast, RTfastTfed, RTfedTfast). The dosing between two consecutive treatment periods will be separated by a minimum 14-day washout interval. This study consists of three periods: a screening period (Day -7\~Day -2), a cross-over treatment period, and a safety follow-up visit (Day 36 \~Day 43). During each treatment period, eligible participants will be admitted to the clinical research unit (CRU) one day prior to dosing and will receive a single oral dose of the assigned study treatment on Day 1 according to the randomized sequence. On Day 1 of each treatment period, T26 or Sporanox® will be administered with 240 mL of water at approximately 8:00 a.m. (±1 hour) under fasted or fed condition. Detailed dietary requirements and dosing procedures. Participants will discharge from the CRU on the fifth day of each treatment period after completion of the scheduled safety assessments and collection of the last PK blood sample (up to 96 hours post-dose).
Conditions
- Fungal Infections
Interventions
Itraconazole Tablet(T26)Drug
Test Product
Sporanox®Drug
Reference Product
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: up to 96 hours post-dose
- AUC0-tlastTime frame: up to 96 hours post-dose
- AUC0-infTime frame: up to 96 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
No. 1, Jialing Yicun, Liangjiang New Area, Chongqing
Chongqing, NA, Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.